VERRICA PHARMACEUTICAL

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

05 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

29 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

05 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

04 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

03 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

15 12 2023 06:00:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

10 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

09 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

25 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

27 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

31 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

24 8 2023 08:30:00 提供 Nasdaq GlobeNewswire

Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

23 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

10 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

08 8 2023 07:30:01 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting

03 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

26 7 2023 16:05:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

21 7 2023 16:24:31 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

31 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

10 5 2023 07:30:00 提供 Nasdaq GlobeNewswire